Profile data is unavailable for this security.
About the company
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
- Revenue in USD (TTM)0.00
- Net income in USD-101.17m
- Incorporated2010
- Employees93.00
- LocationX4 Pharmaceuticals Inc61 NORTH BEACON STREET, 4TH FLOORBOSTON 02134United StatesUSA
- Phone+1 (857) 529-8300
- Fax+1 (302) 655-5049
- Websitehttps://www.x4pharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiff Oncology Inc | 488.00k | -41.47m | 178.26m | 31.00 | -- | 2.56 | -- | 365.29 | -0.9281 | -0.9281 | 0.0109 | 1.56 | 0.0049 | -- | 0.9216 | 15,741.94 | -41.90 | -31.24 | -46.15 | -33.56 | -- | -- | -8,492.01 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Outlook Therapeutics Inc | 0.00 | -51.50m | 182.63m | 24.00 | -- | -- | -- | -- | -3.99 | -3.99 | 0.00 | -1.87 | 0.00 | -- | -- | 0.00 | -122.07 | -214.69 | -441.62 | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -- | 3.00 | -- | -- | -- | 10.70 | -- | -- | -- |
| Codexis Inc | 70.14m | -76.24m | 186.30m | 174.00 | -- | 2.14 | -- | 2.66 | -1.12 | -1.12 | 1.03 | 1.24 | 0.3625 | 5.43 | 2.31 | 403,120.70 | -39.41 | -17.13 | -50.48 | -20.23 | 81.74 | 77.29 | -108.69 | -37.04 | 2.53 | -- | 0.00 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| Candel Therapeutics Inc | 0.00 | -37.94m | 188.70m | 42.00 | -- | 14.68 | -- | -- | -1.31 | -1.31 | 0.00 | 0.4381 | 0.00 | -- | -- | 0.00 | -63.82 | -- | -76.57 | -- | -- | -- | -- | -- | -- | -73.91 | 0.6254 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 0.00 | -101.17m | 189.77m | 93.00 | -- | 3.70 | -- | -- | -0.6026 | -0.6026 | 0.00 | 0.3052 | 0.00 | -- | -- | 0.00 | -66.81 | -61.53 | -78.53 | -69.20 | -- | -- | -- | -13,288.93 | -- | -- | 0.5164 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Atossa Therapeutics Inc | 0.00 | -30.09m | 190.46m | 10.00 | -- | 2.09 | -- | -- | -0.2386 | -0.2386 | 0.00 | 0.7264 | 0.00 | -- | -- | 0.00 | -27.39 | -29.97 | -28.80 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -52.37m | 191.65m | 51.00 | -- | 0.692 | -- | -- | -1.08 | -1.08 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -20.67 | -- | -21.56 | -- | -- | -- | -- | -- | -- | -- | 0.103 | -- | -- | -- | -22.20 | -- | -- | -- |
| Actinium Pharmaceuticals Inc | 81.00k | -48.82m | 192.84m | 49.00 | -- | 4.98 | -- | 2,380.75 | -1.84 | -1.84 | 0.0031 | 1.32 | 0.0008 | -- | -- | 1,653.06 | -49.91 | -46.98 | -55.31 | -52.71 | -- | -- | -60,269.14 | -6,683.95 | -- | -- | 0.0008 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
| Rigel Pharmaceuticals Inc | 116.88m | -25.09m | 192.95m | 147.00 | -- | -- | -- | 1.65 | -0.1444 | -0.1444 | 0.6717 | -0.1638 | 0.9295 | 0.9713 | 3.30 | 795,115.60 | -19.95 | -28.82 | -37.72 | -47.26 | 93.92 | 97.88 | -21.47 | -35.76 | 1.76 | -4.45 | 1.93 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Adverum Biotechnologies Inc | 3.60m | -117.17m | 194.89m | 121.00 | -- | 1.14 | -- | 54.14 | -11.62 | -11.62 | 0.3571 | 8.23 | 0.015 | -- | -- | 29,752.07 | -48.68 | -36.39 | -55.24 | -39.04 | -- | -- | -3,254.58 | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Zevra Therapeutics Inc | 27.46m | -46.05m | 196.29m | 65.00 | -- | 3.03 | -- | 7.15 | -1.29 | -1.29 | 0.7746 | 1.49 | 0.1909 | -- | 2.14 | 422,476.90 | -32.02 | -32.11 | -45.61 | -39.89 | 45.22 | -- | -167.69 | -128.42 | -- | -- | 0.4058 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Poseida Therapeutics Inc | 64.70m | -123.43m | 197.80m | 330.00 | -- | 1.89 | -- | 3.06 | -1.38 | -1.38 | 0.7175 | 1.08 | 0.2068 | -- | 7.15 | 196,069.70 | -39.45 | -40.70 | -49.32 | -47.72 | -- | -- | -190.76 | -233.49 | -- | -14.93 | 0.361 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
| Generation Bio Co | 5.90m | -126.61m | 200.10m | 174.00 | -- | 0.981 | -- | 33.89 | -1.97 | -1.97 | 0.0916 | 3.07 | 0.0157 | -- | 2.71 | 33,931.04 | -33.72 | -36.96 | -36.60 | -39.21 | -- | -- | -2,144.51 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -13.07m | 201.34m | 1.00 | -- | 56.58 | -- | -- | -0.48 | -0.48 | 0.00 | 0.1202 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.40 | 0.0285 | -- | -- | -- | -1,430.39 | -- | -- | -- |
Data as of Apr 25 2024. Currency figures normalised to X4 Pharmaceuticals Inc's reporting currency: US Dollar USD
24.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 7.84m | 4.67% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 7.77m | 4.63% |
| Adage Capital Management LPas of 31 Dec 2023 | 4.28m | 2.55% |
| Sio Capital Management LLCas of 31 Dec 2023 | 3.59m | 2.14% |
| Perceptive Advisors LLCas of 31 Dec 2023 | 3.55m | 2.11% |
| Kingdon Capital Management LLCas of 31 Dec 2023 | 3.47m | 2.07% |
| AXA Investment Managers UK Ltd.as of 31 Dec 2023 | 3.07m | 1.83% |
| Geode Capital Management LLCas of 31 Dec 2023 | 2.80m | 1.67% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.43m | 1.45% |
| Medical Strategy GmbHas of 29 Dec 2023 | 2.04m | 1.21% |
More ▼
Data from 29 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
